Daily Newsletter

30 August 2023

Share with colleague
Subscribe

Daily Newsletter

30 August 2023

Share with colleague
Subscribe

Spotlight

Paper is out but drawbacks remain with eISFs

eISFs have taken over but have they really solved problems sites face or do they introduce new issues for researchers to contend with?

Latest news

FibroGen’s pamrevlumab disappointing results marks second failure in a row

The Phase III trial for FibroGen’s antibody candidate failed to meet its primary endpoint in children with Duchenne muscular dystrophy.

30 August 2023

MTPC pushes win with Parkinson candidate in Phase III trial

Patients in the experimental group of NS0612 showed favourable efficacy over IR-LD/CD with the trial meeting its primary endpoint.

30 August 2023

Roche’s Evrysdi secures EC approval for spinal muscular atrophy in infants

The approval from the European Commission builds on the FDA's approval for usage in patients aged two months and younger.

30 August 2023

Novocure’s tumour-treating electric fields fall short in ovarian cancer trial

The therapy did not improve overall survival rate, but Novacure still highlights promise after exploratory sub-analysis.

30 August 2023

DVCR partners with Clario to provide cardiac data in trials

The platform has a 12-lead telemetry system that archives data on-site and directly uploads it to Clario’s Cloud-based portal.

30 August 2023

Korea grants clearance to Aribio for dementia therapy trial

The company’s Polaris-AD project is currently ongoing with a total of 1,250 patients in Europe, China, Korea and the US.

30 August 2023

Laurent receives approval from Health Canada for Covid therapy trial

Measuring the overall functional health status at week 12 as compared to baseline is the primary endpoint of the study.

30 August 2023

mRNA vaccines represent >40% of the authorized/approved COVID-19 vaccines and boosters in the 7 major pharmaceutical markets

There are currently 13 authorized/approved COVID-19 vaccines in the 7 major pharma markets. Currently, vaccine developers plan to launch updated boosters prior to the upcoming 2023 fall season to target the latest dominant strain, Omicron XBB.1.5. Per GlobalData analysis, mRNA vaccines will likely continue to dominate the market, though as the pandemic winds down, the global COVID-19 vaccines market is expected to decline.